Factors affecting response of chemotherapy in women with ovarian cancer

被引：0
|
作者：
Lubin, J. [1 ]
Markowska, A. [2 ]
Knapp, P. [3 ]
机构：
[1] Clin Oncol Poznan, Dept Gynecol, Poznan, Poland
[2] Inst Gynecol & Obstet, Poznan, Poland
[3] Univ Hosp Bialystok, Dept Gynecol, Bialystok, Poland
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2012年 / 33卷 / 06期
关键词：
Ovarian cancer; Chemotherapy; Factors affecting chemotherapy; MULTIDRUG-RESISTANCE GENE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PRODUCT P-GLYCOPROTEIN; PACLITAXEL RESISTANCE; PROTEIN LRP; E-CADHERIN; EXPRESSION; CLUSTERIN; MDR1; CYCLOOXYGENASE-2;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chemotherapy plays an important role in the treatment of ovarian cancer. Patients' response to chemotherapy is determined by a variety of acknowledged factors, but one might expect that many of them are yet to be described. The aim of this paper was to present the most essential yet still to be generally assessed in clinical practice, factors, which include: E-cadhedrin, hypoxia inducible factor alpha, survivin, COX-2, clusterin, BRCA1 protein, TP53 protein, YY1 protein, multidrug resistance protein, and interleukin-8.
引用
收藏
页码：644 / 647
页数：4
相关论文
共 50 条
  • [1] Factors Affecting the Completion of Intraperitoneal Chemotherapy in Women With Ovarian Cancer
    Robinson, William R.
    Beyer, Julie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 70 - 74
  • [2] Factors affecting receipt of chemotherapy in women with breast cancer
    Morimoto, Libby
    Coalson, Jenna
    Mowat, Fionna
    O'Malley, Cynthia
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2010, 2 : 107 - 122
  • [3] Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer
    Fleming, Nicole D.
    Westin, Shannon N.
    Rauh-Hain, J. Alejandro
    Soliman, Pamela T.
    Fellman, Bryan M.
    Coleman, Robert L.
    Meyer, Larissa A.
    Shafer, Aaron
    Cobb, Lauren P.
    Jazaeri, Amir
    Lu, Karen H.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2021, 162 (01) : 65 - 71
  • [4] BRCA1 and implications for response to chemotherapy in ovarian cancer
    Quinn, Jennifer E.
    Carser, Judith E.
    James, Colin R.
    Kennedy, Richard D.
    Harkin, D. Paul
    GYNECOLOGIC ONCOLOGY, 2009, 113 (01) : 134 - 142
  • [5] Factors affecting the Fatigue of Hospitalized Women Cancer Patients Receiving Chemotherapy
    Kim, Kyunghee
    Lee, MyoSuk
    Kwak, Yeunhee
    Kim, Ji-Su
    ASIAN ONCOLOGY NURSING, 2014, 14 (03) : 182 - 190
  • [6] Risk factors for deep venous thrombosis in women with ovarian cancer
    Ebina, Yasuhiko
    Uchiyama, Mihoko
    Imafuku, Hitomi
    Suzuki, Kaho
    Miyahara, Yoshiya
    Yamada, Hideto
    MEDICINE, 2018, 97 (23)
  • [7] Continued Chemotherapy After Complete Response to Primary Therapy Among Women With Advanced Ovarian Cancer
    Hess, Lisa M.
    Rong, Nan
    Monahan, Patrick O.
    Gupta, Paridha
    Thomaskutty, Champ
    Matei, Daniela
    CANCER, 2010, 116 (22) : 5251 - 5260
  • [8] Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer
    O'Connor, Tracey L.
    Edge, Stephen B.
    Kossoff, Ellen B.
    Groman, Adrienne
    Wilding, Gregory E.
    Ademuyiwa, Foluso O. .
    Levine, Ellis G.
    Watroba, Nancy
    Ngamphaiboon, Nuttapong
    JOURNAL OF GERIATRIC ONCOLOGY, 2012, 3 (04) : 320 - 328
  • [9] Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy
    Polverino, G
    Parazzini, F
    Stellato, G
    Scarfone, G
    Cipriani, S
    Bolis, G
    GYNECOLOGIC ONCOLOGY, 2005, 99 (02) : 343 - 347
  • [10] The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer
    Wambecke, Anais
    Ahmad, Mohammad
    Lambert, Bernard
    Joly, Florence
    Poulain, Laurent
    Denoyelle, Christophe
    Meryet-Figuiere, Matthieu
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 726 - 733
12345